Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
50 hedge funds and large institutions have $39.2M invested in Merrimack Pharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 15 reducing their positions, and 7 closing their positions.
3% more capital invested
Capital invested by funds: $37.9M → $39.2M (+$1.27M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 54 → 50 (-4)
20% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 15
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.9M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$2.85M |
| 3 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$1.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$916K |
| 5 |
2L
22NW LP
Seattle,
Washington
|
+$901K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$524K |
| 2 |
CC
Cannell & Co
New York
|
-$347K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$251K |
| 4 |
JP Morgan Chase
New York
|
-$200K |
| 5 |
Goldman Sachs
New York
|
-$184K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
| – | -$24K | -4,357 | Closed |
|
52
Fidelity Investments
Boston,
Massachusetts
| – | -$308 | -65 | -58% |
|
|
JFA
53
JNBA Financial Advisors
Bloomington,
Minnesota
| – | +$62 | +13 | New |
|
MACK Hedge Fund Activity: Q2 2019 in Review
50 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q2 2019, worth a combined $39.2M — up 3.3% from $37.9M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of MACK and 4 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 12 added.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $3.9M. The largest seller was D.E. Shaw & Co, cutting an estimated $524K.
- 50 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q2 2019, down from 54 in Q1 2019.
- Funds reported $39.2M of Merrimack Pharmaceuticals, Inc. stock for Q2 2019, up 3.3% quarter-over-quarter.
- 4 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q2 2019 and 7 closed out, a net change of -3 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q2 2019 was Nantahala Capital Management, an estimated $3.9M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q2 2019 was D.E. Shaw & Co, an estimated $524K sold.
Based on aggregated 13F filings for Q2 2019.